Current Report Filing (8-k)
March 29 2019 - 11:29AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
March 29, 2019
Nexien
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Commission
File No.:
0-55320
Delaware
|
|
26-2049376
|
(State
or other jurisdiction of incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
4340
E Kentucky Ave, Suite 206, Glendale, CO
|
|
80246
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (303) 495-7583
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
In
lieu of an annual meeting of the stockholders of the registrant, by written consent of the holders of a majority of the outstanding
shares of common stock dated March 4, 2019, the following actions were taken, which are effective as of March 29, 2019:
|
●
|
The
registrant’s board of directors, as previously reported to the Commission in the registrant’s filings, was re-elected
in its entirety;
|
|
●
|
The
2018 Equity Incentive Plan was approved; and
|
|
●
|
The
registrant’s selection of M&K CPAS (“M&K”) as its independent registered public accounting firm
was ratified.
|
Additional
information regarding these matters may be found in the registrant’s Information Statement filed on March 8, 2019.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
NEXIEN
BIOPHARMA, INC.
|
|
|
|
/s/:
Alex Wasyl
|
|
Alex
Wasyl, Chief Executive Officer
|
|
March
29, 2019
|
|
Nexien BioPharma (QB) (USOTC:NXEN)
Historical Stock Chart
From May 2024 to Jun 2024
Nexien BioPharma (QB) (USOTC:NXEN)
Historical Stock Chart
From Jun 2023 to Jun 2024